Where is QED located?

QED is headquartered in Palo Alto, United States.

Who is the current CEO of QED?

Neil Kumar of QED. They have also founded 3 companies and are an angel investors in 1 startup.

How many employees does QED have?

As of Jul 01, 2024, the latest employee count at QED is 65.

Is QED a funded company?

QED is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does QED rank among its competitors?

QED ranks 1181st amongst 3229 active competitors, of which 1113 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Bio, which secured $40M in May, 2026.

Who are the top competitors of QED?

QED's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Senti Bio secured the most recent funding round in May, 2026.

QED - 2026 Company Profile, Team & Competitors

Company Details

QED Therapeutics is a subsidiary of BridgeBio developing therapies for rare pediatric diseases and cancer. The company is developing drugs which are fibroblast growth factor receptors (FGFR). The company's lead candidate, Infigratinib is an FGFR (TKI) inhibitor and being developed FGFR-driven cholangiocarcinoma (phase 3), metastatic urothelial carcinoma (phase1), and achondroplasia.

Website: qedtx.com
Email ID: *****@qedtx.com
Phone Number: +1 **********
Part Of

Key Metrics

Founded Year

2017

Location

Palo Alto, United States

Stage

Unfunded

Ranked

1181^st among 3229 active competitors

Employee Count

65 as on Jul 01, 2024

Similar Companies

Jazz Pharmaceuticals & 2968 more

View QED's full profile

QED has not raised any funding rounds yet.

The founders of QED is Neil Kumar. Neil Kumar is the CEO of QED.

Here are the details of QED's key team members:

Neil Kumar: Founder & CEO of QED and founder of 2 other companies, BridgeBio and Eidos Therapeutics. They are also an angel investor in 1 startup.
Contact Info: 1 email address

View details of QED's Founder profiles and Board Members

QED's employee count trend

QED has 65 employees as of Jul 24. Here is QED's employee count trend over the years:

Uncover QED's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of QED include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of QED, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
7th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
8th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
10th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
1181st	QED 2017, Palo Alto (United States), Unfunded	Developer of tyrosine kinase inhibitors targeting FGFR-driven cancers	-	-	38/100